Lesson 1

Health Professional Version

Ischemic Stroke

Laser tPBM has been evaluated in both preclinical stroke models and human trials. In the rabbit small-clot embolic stroke model, transcranial 808 nm laser applied within 3 to 6 hours improved clinical rating scores in a dose-dependent manner; increasing power density from 7.5 mW/cm² to 25 mW/cm² extended the therapeutic window. The clinical NEST-1 trial demonstrated that 808 nm laser initiated within 24 hours of ischemic stroke was safe and associated with better outcomes on the NIH Stroke Scale. Subsequent NEST-2 and NEST-3 trials yielded mixed results, though post-hoc analyses suggested that unilateral application to the affected hemisphere—rather than whole-head treatment—may be critical for efficacy. In chronic left-hemisphere stroke patients with aphasia, Naeser and colleagues reported significant naming improvements after 18 laser treatments applied only to the affected side, with no benefit from bilateral irradiation.

Traumatic Brain Injury

Preclinical laser evidence in TBI is robust. In a controlled cortical impact mouse model, repeated 810 nm transcranial laser improved neurological performance, reduced lesion size, and enhanced neuroprogenitor cell proliferation. In human TBI, a prospective, double-blind, placebo-controlled trial of moderate TBI patients using a low-level light helmet (LED-based) found no adverse events and measurable neuroreactivity on diffusion tensor imaging, though symptom scores did not separate significantly from sham. By contrast, open-label trials using multi-watt Class IV near-infrared lasers (Neuro-Luminance protocol) in chronic mild-to-moderate TBI reported significant and sustained improvements in headache, cognition, sleep, and mood. Physics modeling indicates that less than 1% of incident light from low-power LEDs reaches the brain parenchyma, whereas multi-watt laser systems achieve the fluence necessary for cortical and subcortical engagement.

Major Depressive Disorder

Published laser trials in depression show consistent biological engagement and promising clinical signals. Near-infrared transcranial laser therapy (NIR-TLT) was first shown by Schiffer and colleagues to relieve MDD symptoms without significant side effects. Cassano and colleagues subsequently demonstrated that tPBM with NIR laser increased prefrontal cortex metabolism and produced antidepressant effects. In a meta-analysis of controlled trials, photobiomodulation improved depressive symptoms with a standardized mean difference of −0.55 compared with sham. Notably, an open-label multi-watt infrared laser trial in 39 patients with MDD reported a 92% response rate and 82% remission rate, with onset of benefit within four sessions and sustained improvement at long-term follow-up.

Neurodegenerative Disease

Alzheimer’s Disease

In transgenic rodent models, 808 nm laser reduced Aβ-induced mitochondrial dysfunction, tau pathology, and oxidative damage while enhancing total antioxidant capacity. A 1267 nm laser protocol has been shown to stimulate meningeal lymphatic clearance of Aβ during sleep, improving recognition memory. In human studies, Berman and colleagues reported that 1060–1080 nm laser treatment improved cognitive and memory performance in AD patients over 28 days. Recent dementia cohorts treated with tPBM showed cognitive and mood improvements, though durability beyond one month post-treatment remains under investigation.

Parkinson’s Disease

In MPTP-induced mouse models, 670 nm and 810 nm laser prevented loss of tyrosine hydroxylase–positive neurons and reduced cerebrovascular leakage in the substantia nigra. Clinically, targeting the brainstem with 940 nm laser combined with molecular hydrogen significantly reduced Unified Parkinson Disease Rating Scale scores, with benefits persisting at one-week follow-up. Systemic (abdominal) laser application has also been explored based on gut-brain axis mechanisms.

PSYCHIATRIC AND NEURODEVELOPMENTAL CONDITIONS

The Brain Photobiomodulation Clinic at Massachusetts General Hospital currently offers tPBM for treatment-resistant major depressive disorder, generalized anxiety disorder, and PTSD. Clinical and preclinical studies also support applications in autism spectrum disorder, ADHD, Down syndrome, and opioid addiction, with reported improvements in social functioning, attention, and mood regulation.

PAIN AND FUNCTIONAL DISORDERS

tPBM is being explored for fibromyalgia, where dysfunctional pain network connectivity makes neuromodulation a plausible intervention. One clinical series reported significant reductions in pain scores when tPBM was used as an adjunct to stable pharmacotherapy. Research is also investigating its use for residual sleepiness in sleep apnea patients and for insomnia.